SAN

80.24

-1.64%↓

UCB

237.4

-3.73%↓

SHL.DE

35.42

-1.69%↓

ARGX

666.6

-2.49%↓

VIE

35.59

+0.08%↑

SAN

80.24

-1.64%↓

UCB

237.4

-3.73%↓

SHL.DE

35.42

-1.69%↓

ARGX

666.6

-2.49%↓

VIE

35.59

+0.08%↑

SAN

80.24

-1.64%↓

UCB

237.4

-3.73%↓

SHL.DE

35.42

-1.69%↓

ARGX

666.6

-2.49%↓

VIE

35.59

+0.08%↑

SAN

80.24

-1.64%↓

UCB

237.4

-3.73%↓

SHL.DE

35.42

-1.69%↓

ARGX

666.6

-2.49%↓

VIE

35.59

+0.08%↑

SAN

80.24

-1.64%↓

UCB

237.4

-3.73%↓

SHL.DE

35.42

-1.69%↓

ARGX

666.6

-2.49%↓

VIE

35.59

+0.08%↑

Search

Merck KGaA

Gesloten

SectorGezondheidszorg

111.65

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

111.55

Max

112.05

Belangrijke statistieken

By Trading Economics

Inkomsten

250M

902M

Verkoop

63M

5.3B

Dividendrendement

1.34

Winstmarge

16.961

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+23.16% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

1.34%

2.24%

Volgende Winsten

13 mei 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

98B

Vorige openingsprijs

111.65

Vorige sluitingsprijs

111.65

Nieuwssentiment

By Acuity

16%

84%

71 / 348 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

Merck KGaA Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

5 mrt 2026, 06:28 UTC

Winsten

Germany's Merck KGaA Expects Currency Headwinds to Weigh on Earnings

13 nov 2025, 13:40 UTC

Winsten

Germany's Merck KGaA Shares Rise After Semiconductor, Pharma Demand Boost Results -- Update

13 nov 2025, 06:24 UTC

Winsten

Germany's Merck KGaA Posts Higher Earnings on Organic Growth Across Units

1 apr 2026, 12:06 UTC

Acquisities, Fusies, Overnames

Merck KGaA Completes Acquisition of JSR Life Sciences' Chromatography Business

5 mrt 2026, 08:40 UTC

Marktinformatie

Germany's Merck KGaA Issues Weaker-Than-Expected Guidance -- Market Talk

5 mrt 2026, 06:00 UTC

Winsten

Merck KGaA Sees 2026 Ebitda Before Special Items at EUR5.5B-EUR6B

5 mrt 2026, 06:00 UTC

Winsten

Merck KGaA Sees 2026 Adj EPS EUR7.10-Adj EPS EUR8

5 mrt 2026, 06:00 UTC

Winsten

Analysts Saw Merck KGaA 2025 Ebitda Before Special Items EUR6.1B

5 mrt 2026, 06:00 UTC

Winsten

Merck KGaA Sees 2026 Sales EUR20B-EUR21B

5 mrt 2026, 06:00 UTC

Winsten

Merck KGaA Sees 2026 Organic Net Sales Ranging From 1% Fall to 2% Rise

5 mrt 2026, 06:00 UTC

Winsten

Merck KGaA 2025 Adj EPS EUR8.34

5 mrt 2026, 06:00 UTC

Winsten

Analysts Saw Merck KGaA 2025 Net Sales at EUR21.14B

5 mrt 2026, 06:00 UTC

Winsten

Merck KGaA Expects Considerable Foreign-Exchange Headwinds in 2026

5 mrt 2026, 06:00 UTC

Winsten

Merck KGaA Keeps Dividend at EUR2.20 a Share

5 mrt 2026, 06:00 UTC

Winsten

Merck KGaA 2025 After-Tax Profit EUR2.615B

5 mrt 2026, 06:00 UTC

Winsten

Germany's Merck KGaA Says Organic Net Sales Grew 3.1% in 2025

5 mrt 2026, 06:00 UTC

Winsten

Merck KGaA 2025 Sales EUR21.1B

5 mrt 2026, 06:00 UTC

Winsten

Merck KGaA 2025 Ebitda Before Special Items EUR6.11B

12 feb 2026, 15:20 UTC

Winsten

Sanofi Shares Fall After CEO Change -- Update

20 jan 2026, 09:54 UTC

Marktinformatie
Acquisities, Fusies, Overnames

DAVOS: Merck KGaA Not in a Hurry for M&A, CEO Says -- Market Talk

13 nov 2025, 07:57 UTC

Marktinformatie
Winsten

Germany's Merck KGaA Beats Expectations With Strong Results -- Market Talk

13 nov 2025, 06:00 UTC

Winsten

Merck KGaA Sees 2025 Ebitda Before Exceptional Items at EUR6B-EUR6.2B

13 nov 2025, 06:00 UTC

Winsten

Merck KGaA Narrows 2025 View To Sales EUR20.8B-EUR21.4B

13 nov 2025, 06:00 UTC

Winsten

Merck KGaA Sees 2025 Organic Ebitda Before Exceptional Items Growth of 5%-7%

13 nov 2025, 06:00 UTC

Winsten

Merck KGaA Had Guided for 2025 Organic Sales Growth of 2% to 5%

13 nov 2025, 06:00 UTC

Winsten

Merck KGaA Says Guidance Midpoint Remains Unchanged

13 nov 2025, 06:00 UTC

Winsten

Merck KGaA Had Guided for 2025 Organic Ebitda Before Exceptional Items Growth of 4%-8%

13 nov 2025, 06:00 UTC

Winsten

Merck KGaA Sees 2025 Organic Sales Growth of Around 3%

13 nov 2025, 06:00 UTC

Winsten

Merck KGaA 3Q After-Tax Profit EUR898M

13 nov 2025, 06:00 UTC

Winsten

Merck KGaA: 3Q Net Sales Rose 5.2% Organically With Solid Growth Across Sectors

Peer Vergelijking

Prijswijziging

Merck KGaA Prognose

Koersdoel

By TipRanks

23.16% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 138 EUR  23.16%

Hoogste 152 EUR

Laagste 112 EUR

Gebaseerd op 8 Wall Street-analisten die 12-maands prijsdoelen bieden voor Merck KGaA - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

8 ratings

5

Buy

3

Hold

0

Sell

Technische score

By Trading Central

121.15 / 123.55Steun & Weerstand

Korte Termijn

Strong Bearish Evidence

Gemiddeld Termijn

Neutral Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

71 / 348 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Merck KGaA

There is no Profile data available for MRK.BE.
help-icon Live chat